Paolo Bidoli

Monza, 20900, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature.

Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature.

Journal: Immunotherapy

Published: December 07, 2021

Anti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer.

Anti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer.

Journal: Frontiers in bioscience (Scholar edition)

Published: April 03, 2021

Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma.

Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma.

Journal: Cancers

Published: January 22, 2021

Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.

Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 07, 2020

Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects.

Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects.

Journal: Cancers

Published: September 28, 2020

High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases.

High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases.

Journal: Frontiers in oncology

Published: August 20, 2020

Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab.

Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab.

Journal: Immunotherapy

Published: May 19, 2020

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 16, 2020

Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.

Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.

Journal: Clinical lung cancer

Published: March 31, 2020

Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale.

Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale.

Journal: European journal of cancer care

Published: February 18, 2020

New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.

New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.

Journal: Cells

Published: February 01, 2020

Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review.

Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 18, 2019

Showing 1-12 of 67

Last Updated: 09/26/2026